Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index; 79 of the 180 sources its claims cite were checked for support.

Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits

Open access
Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., Hall, W. · 2025 · European Archives of Psychiatry and Clinical Neuroscience

Abstract

The legalization of cannabis for medical and recreational purposes has progressed internationally. Chronic patterns of cannabis use have been associated with disrupted learning, impaired cognitive performance, reduced educational attainment, cannabis use disorder, psychosis/schizophrenia, mood and anxiety disorders, and suicidal behaviors among adolescents and young adults.

Overview

CoChat Summary

TL;DR

This 2024 review summarizes evidence that recreational cannabis use, especially frequent high-THC use, is linked to acute impairment and several longer-term mental and physical health risks, while medical cannabinoid benefits are limited to a few indications. The strongest therapeutic evidence is for CBD in refractory epilepsy, with smaller benefits for spasticity, chronic pain, and chemotherapy-induced nausea/vomiting.

Key findings

  • The review states that regular use of high-THC products can produce cannabis use disorder (CUD), and that 22% of people who ever use cannabis meet criteria for CUD, rising to 33% among weekly or daily users.
  • Acute consumption of high THC doses can cause time-limited mental, gastrointestinal, and cardiovascular problems and motor vehicle accidents; the paper reports traffic-accident odds ratios ranging from 1.25 to 1.97.
  • For psychosis, meta-analyses found a robust association with cannabis use and a dose–response relationship; one multinational study reported that daily use of high-potency cannabis increased psychosis risk fivefold versus non-users, while daily low-potency use doubled risk.
  • For medicinal use, the paper says cannabinoids have small beneficial effects for muscle spasticity, limited/inconsistent evidence for chronic pain, higher antiemetic effects than placebo or conventional anti-emetics for CINV, and that CBD is moderately efficacious for refractory epilepsy in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.

Methods

  • The paper is a selective literature review intended to update a prior systematic literature search on “benefits and risks of cannabinoids” commissioned by the German Ministry of Health.
  • Searches were conducted in PubMed and the Cochrane Central Register of Clinical Trials for 10.5.2016 to 10.5.2023, prioritizing systematic reviews and meta-analyses from the past decade; when unavailable, the authors included strong, adequately powered studies published since the most recent review.
  • The references of included studies were screened for additional relevant studies, and the authors used the causal-inference approach outlined in their Text Box 1.

Limitations

  • The authors explicitly note that the literature is sparse for some questions, including increased cannabis potency and its effects, and that more rigorous data is needed on outcomes associated with potency, product diversity, and new routes of administration.
  • They state that confounding by tobacco and other drug use complicates interpretation of long-term harms, and that case-control and cohort studies are subject to unmeasured confounding.
  • Evident from the text: the review is selective rather than a full systematic review of all cannabis evidence, and much of the therapeutic literature is described as limited, heterogeneous, or insufficient for guidance.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00406-024-01880-2

Cites

118 of 118 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

68 Valid · 3 Not valid · 68 Not checked · 39 Own results and interpretations

124 more claims · 46 with their cited sources checked

Create a free account to see all 178 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 40
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Citations

Cites

Show all 119 references

Research works printed but not linked: 1

  1. Hoch E, Friemel C, Schneider M (2019) Cannabis: benefits and risks. Springer, Heidelberg

Cited by

See all 139

Metadata

Authors
Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W.
Affiliations
  • LMU Klinikum (DE)
  • National Institute on Alcohol Abuse and Alcoholism (US)
  • IFT Institut für Therapieforschung (DE)
  • Australian Catholic University (AU)
  • University of Bath (GB)
  • The University of Queensland (AU)
Corresponding author
Hoch, E.
Venue
European Archives of Psychiatry and Clinical Neuroscience
Published
2024-09-19
Volume
275
Issue
2
Pages
281-292
ISSN
  • 0003-9373 (ISSN-L)
  • 0940-1334
  • 1433-8491
OpenAlex
W4402698048
Cited by
139
References
119
Citations by year
2026: 86 · 2025: 52 · 2024: 1
FWCI
8.68
Type
journal article
Language
en
Open access
Licence
Locations
  • European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
Funders
Klinikum der Universität München
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Keywords
cannabis, cannabinoids, delta-9-tetrahydrocannabinol, recreational cannabis use, medical cannabis, cannabis use disorder, adolescent cannabis use, psychosis, schizophrenia, cognitive impairment, prenatal cannabis exposure, cannabidiol, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, cannabis legalization
MeSH terms
Cannabinoids, Cannabis, Marijuana Abuse, Humans, Dronabinol, Medical Marijuana

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. https://app.cochat.ai/papers/10.1007/s00406-024-01880-2
The paper
Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01880-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.